TCRR News and Press, TCR2 Therapeutics Inc. From 12/11/20

Gainers: [[TCRR]] +28.7%. [[NSCO]] +15.8%. [[DBX]] +9.2%. [[DPW]] +4%.  [[GIK]] +3.2%.Losers: [[MYGN]] -8.6%. [[IMAB]] -6%. [[TPGY]] -5%. [[MDLY]] -4%. [[AIV]] -3.9%. For further details see: DBX, MYGN, DPW and AIV among after-hours movers

TCR2 Therapeutics (TCRR): Q3 GAAP EPS of -$0.56.Cash, cash equivalents, and investments of $246.7M.Press Release For further details see: TCR2 Therapeutics reports Q3 results

- Consistent progress of TC-210 with interim update from Phase 1/2 trial anticipated in 4Q20 - Additional clinical sites to include UCSF Medical Center and Princess Margaret Cancer Centre in the TC-210 Phase 1/2 clinical trial - Agreement with ElevateBio for additional manufacturi...

TCR2 Therapeutics (TCRR) has established a manufacturing partnership with ElevateBio, to leverage the extensive technical capabilities at ElevateBio BaseCamp, a cell and gene therapy manufacturing facility based in Waltham, MA. The partnership will focus on the production of TC-210, TCR2 ...

- ElevateBio BaseCamp to support anticipated TC-210 Phase 2 clinical trial demand CAMBRIDGE, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing a pipeline of novel T cell therapies for patients sufferi...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha, Apple Po...

CAMBRIDGE, Mass., Sept. 29, 2020 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that management will participate in a fireside chat at the Je...

CAMBRIDGE, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that Ian Somaiya, Chief Financial Officer of TCR 2  Therape...

TCR2 Therapeutics (NASDAQ: TCRR ) : Q2 GAAP EPS of -$0.67 misses by $0.03 . More news on: TCR2 Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

- TC-210 patient with partial response confirmed by independent central review and tumor regression improved further from 42% to 75% - Began dosing of TC-110 in the Phase 1/2 trial for patients with CD19+ NHL or adult ALL - Addition of MD Anderson Cancer Center, a leading clinical site...